Daily Variability in Mineral Metabolites in CKD and Effects of Dietary Calcium and Calcitriol
Authors:
Open Access
- 1 May 2012
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 7 (5) , 820-828
Abstract
Summary: Background and objectives: Primary prevention of disordered mineral metabolism in CKD necessitates knowledge of its early pathophysiology. This study evaluated daily fluctuations in mineral metabolites in patients with CKD stages 3 and 4 before and after short-term calcitriol treatment and tested the effects of dietary calcium and calcitriol supplementation on these parameters in the dynamic postprandial setting. Design, setting, participants, & measurements: Twelve CKD patients received calcitriol (0.25 μg daily for 1 week) with hourly assessments of mineral metabolites made throughout the day and in the context of standardized meals before and after treatment. Calcium content (250 versus 500 mg) in the breakfasts constituted the dietary calcium intervention. Twelve healthy volunteers were used as controls. Results: At baseline, compared with controls, fasting CKD subjects had higher parathyroid hormone and fibroblast growth factor 23 levels and greater fractional excretion of phosphate. After breakfast, urinary calcium excretion increased and parathyroid hormone levels dipped transiently in both groups, but they rose soon thereafter, reaching higher peaks in CKD. Calcitriol decreased fasting parathyroid hormone levels, and when combined with dietary calcium load, it normalized the postprandial parathyroid and calcemic responses. Daily variability in mineral metabolites was preserved in CKD before and after calcitriol. Fibroblast growth factor 23 levels increased after calcitriol, although the response was heterogeneous. Conclusions: Short-term treatment with calcitriol and dietary calcium supplementation normalizes the parathyroid and calcemic postprandial responses in patients with CKD, in whom the diurnal rhythms of mineral metabolites are preserved. Future studies should investigate the variable fibroblast growth factor 23 response to calcitriol in CKD.Keywords
This publication has 29 references indexed in Scilit:
- Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium dietsKidney International, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency CohortNephrology Dialysis Transplantation, 2011
- Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid StatusThe Journal of Clinical Endocrinology & Metabolism, 2010
- Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney diseaseKidney International, 2010
- Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in Early CKDJournal of the American Society of Nephrology, 2008
- Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorptionProceedings of the National Academy of Sciences, 2007
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004